ライフサイエンスコーパス: ischemic stroke

1 and odds ratio, 0.62; 95% CI, 0.50-0.77 for ischemic stroke).

2 n, 0.1% with stent thrombosis, and 0.1% with ischemic stroke).

3 diovascular death, myocardial infarction, or ischemic stroke.

4 id cycle intermediates in mouse brain during ischemic stroke.

5 riod, 3529 women and 5370 men experienced an ischemic stroke.

6 mbolism, defined as myocardial infarction or ischemic stroke.

7 dite motor rehabilitation after suffering an ischemic stroke.

8 ryptogenic stroke accounts for 30% to 40% of ischemic stroke.

9 th a null relationship of sodium intake with ischemic stroke.

10 een patients had either device thrombosis or ischemic stroke.

11 ide novel insights into the genetic basis of ischemic stroke.

12 the exact composition of thrombi that cause ischemic stroke.

13 lar disease event, and secondary outcome was ischemic stroke.

14 icroRNAs in vascular and neural damage after ischemic stroke.

15 Similar results were observed in ischemic stroke.

16 ithheld in these complex patients with acute ischemic stroke.

17 entional treatment (control group) for acute ischemic stroke.

18 inactivation of EphA2 reduces BBB damage in ischemic stroke.

19 r withholding tPA therapy from patients with ischemic stroke.

20 d received mechanical thrombectomy for acute ischemic stroke.

21 diovascular death, myocardial infarction, or ischemic stroke.

22 levels are differentially regulated in acute ischemic stroke.

23 thrombolytic potential in treatment of acute ischemic stroke.

24 he extent of BBB damage using a rat model of ischemic stroke.

25 in the unmet high medical need indication of ischemic stroke.

26 d are positively associated with early adult ischemic stroke.

27 dence and improves the functional outcome of ischemic stroke.

28 stigated the association between PPI use and ischemic stroke.

29 racranial bleeding are unique from those for ischemic stroke.

30 translational thromboembolic model of acute ischemic stroke.

31 ndovascular treatment in patients with acute ischemic stroke.

32 ture are prevalent in children with arterial ischemic stroke.

33 system in both pathology and recovery after ischemic stroke.

34 d breaking changes in the treatment of acute ischemic stroke.

35 sm, chronic kidney disease, and large-artery ischemic stroke.

36 z score was positively associated with early ischemic stroke.

37 romotes neurological recovery after an acute ischemic stroke.

38 utely symptomatic carotid disease and recent ischemic stroke.

39 g cancer, in cerebrovascular pathogenesis of ischemic stroke.

40 lly those who have previously experienced an ischemic stroke.

41 neuroprotection in an animal model of acute ischemic stroke.

42 nded strategies to reduce DTN times in acute ischemic stroke.

43 l damage and improve the clinical outcome of ischemic stroke.

44 s highly neuroprotective in a focal model of ischemic stroke.

45 nd functional outcome in patients with acute ischemic stroke.

46 fy potential genetic factors contributing to ischemic stroke.

47 A (5 and 10 mg/kg) for 4 wk and subjected to ischemic stroke.

48 infections are common causes of HIV-related ischemic stroke.

49 the aging population and implicated in many ischemic strokes.

50 ed RR=0.76%; number needed to treat=132) and ischemic stroke (0.63% versus 1.38%; RR=0.45; 95% confid

51 id not have significantly different rates of ischemic stroke (0.80 vs. 0.94 events per 100 person-yea

52 ed RR=0.43%; number needed to treat=233) and ischemic strokes (0.48% versus 0.91%; RR=0.53; 95% confi

53 ed with alteplase for the treatment of acute ischemic stroke, 1 that demonstrated superiority of tene

54 .00 (0.74-1.35) for MI, 0.93 (0.71-1.22) for ischemic stroke, 1.58 (1.17-2.12) for CV-associated deat

55 .57 (1.14-2.17) for MI, 1.33 (1.01-1.76) for ischemic stroke, 1.95 (1.42-2.67) for CV-associated deat

56 incident coronary heart disease events, 548 ischemic strokes, 1395 heart failure events, and 2793 de

57 : T2DM (26,488/83,964), CHD (54,501/68,275), ischemic stroke (14,779/67,312), and HF (4,526/18,400).

58 er recent transient ischemic attack or minor ischemic stroke: 18 patients with culprit carotid stenos

59 in, driven by a significant 21% reduction in ischemic stroke (3.4% versus 4.1%; HR, 0.79; 95% CI, 0.6

60 h DM were in myocardial infarction (24%) and ischemic stroke (39%).

61 uing warfarin treatment had a higher rate of ischemic stroke (5 events in 312 years at risk [1.6% per

62 60; 95% CI, 0.38-0.95; P=0.030) and 7.6% for ischemic stroke (8.7% versus 16.3%; number needed to tre

63 have major risk factors or other causes for ischemic stroke (82%).

64 atency in acute thrombotic disorders such as ischemic stroke, acute coronary syndrome, or acute limb

65 atients with AF (n=6772) had higher risks of ischemic stroke (adjusted hazard ratio [aHR], 1.27; 95%

66 Intracerebral hemorrhage and ischemic stroke admissions were identified from the Nati

67 ata from a cohort of 2 437 975 patients with ischemic stroke admitted to 2222 participating hospitals

68 significant association between PPI use and ischemic stroke, after accounting for indications for PP

69 Timely reperfusion is critical in acute ischemic stroke (AIS) and ST-segment-elevation myocardia

70 ves clinical outcomes in patients with acute ischemic stroke (AIS) caused by a large vessel occlusion

71 ween thyroid hormones and prognosis of acute ischemic stroke (AIS) reported conflicting results.

72 Patients with acute ischemic stroke (AIS) suffer from infections associated

73 ombectomy (MT) is recommended to treat acute ischemic stroke (AIS) with a large vessel occlusion (LVO

74 hey are also frequently observed after acute ischemic stroke (AIS), indicating poor functional outcom

75 ent use of intravenous thrombolysis in acute ischemic stroke (AIS).

76 th better neurologic outcome following acute ischemic stroke (AIS).

77 ssociated with an increased risk of arterial ischemic stroke (AIS).

78 fections, one myocardial infarction, and one ischemic stroke among the patients who received tofaciti

79 The incidence of ischemic stroke among young adults is rising and is pote

80 uring follow-up, 382 (6.5%) participants had ischemic stroke and 395 (6.7%) had MI with 1 or more dis

81 Patients who presented with acute ischemic stroke and a large vessel occlusion in the ante

82 are two to four times more likely to have an ischemic stroke and are less likely to regain functions

83 ular events including myocardial infarction, ischemic stroke and cardiovascular death, quality-adjust

84 Ischemic stroke and clinically significant bleeding even

85 ovascular hemorrhage in mouse models of both ischemic stroke and glioblastoma, accompanied by reduced

86 nce interval (CI): 1.03-1.29], ED visits for ischemic stroke and heat waves defined by minimum temper

87 Here we show that in patients with ischemic stroke and in mice subjected to middle cerebral

88 was not significant, but it was positive for ischemic stroke and inverse for hemorrhagic stroke.

89 SVS comprises one quarter of all ischemic stroke and is a major manifestation of cerebral

90 rvational study of 94474 patients with acute ischemic stroke and known history of AF admitted from Oc

91 revascularization among patients with acute ischemic stroke and large vessel occlusion.

92 Ischemic stroke and MI.

93 Ischemic stroke and severe white matter lesions were mor

94 terns and associated outcomes, i.e., stroke (ischemic stroke and systemic embolism) and major bleedin

95 hip with the rate of cardiovascular death/MI/ischemic stroke and the individual components (P for tre

96 and change in BMI are associated with adult ischemic stroke and to assess whether the associations a

97 SRP in predicting the risk of all-stroke and ischemic stroke and validated this new FSRP in 2 externa

98 Primary outcomes of inpatient admissions for ischemic strokes and major bleeding were compared across

99 ism accounts for an increasing proportion of ischemic strokes and might multiply several-fold during

100 d to stent thrombosis, stent thrombosis, and ischemic stroke) and bleeding events (Global Utilization

101 d to stent thrombosis, stent thrombosis, and ischemic stroke) and bleeding events (GUSTO classificati

102 tion, 113 with stent thrombosis, and 83 with ischemic stroke), and 232 individuals (2.0%) had 235 ble

103 encephalopathy, and 5 with neonatal arterial ischemic stroke), and 5 were presumed perinatal hemorrha

104 ) with myocardial infarction, 11 (0.9%) with ischemic stroke, and 1 (0.1%) with deep venous thrombosi

105 lerotic stenosis (ICAS) is a common cause of ischemic stroke, and a low level of high-density lipopro

106 included a composite of mortality, clinical ischemic stroke, and acute kidney injury within 30 days

107 ng fatal and nonfatal myocardial infarction, ischemic stroke, and cardiovascular death.

108 , hospitalization for myocardial infarction, ischemic stroke, and heart failure.

109 (atrial fibrillation </=30 days of surgery), ischemic stroke, and mortality.

110 arotid web as well as their association with ischemic stroke, and to determine the interobserver agre

111 o reticularis, polyarteritis nodosa, lacunar ischemic strokes, and intracranial hemorrhages), immunod

112 ing numerous pathologies including migraine, ischemic stroke, aneurysmal subarachnoid hemorrhage, int

113 c stroke (NAIS), arterial presumed perinatal ischemic stroke (APPIS), or fetal periventricular venous

114 All patients with acute ischemic stroke are in need of hyperacute secondary prev

115 ects, those with congestive heart failure or ischemic stroke as their index event, betrixaban reduced

116 To avoid the occurrence of early ischemic stroke associated with childhood overweight and

117 VT was provided to 3.3% of all patients with ischemic stroke at all hospitals, representing 15.1% of

118 y is steeper after than before the event for ischemic stroke but not myocardial infarction (MI).

119 red a promising neuroprotective treatment of ischemic stroke, but the treatment's various complicatio

120 Childhood arterial ischemic stroke (CAIS) affects approximately 1.6 per 100

121 esses of transient ischemic attack and minor ischemic stroke care.

122 ents with transient ischemic attack or minor ischemic stroke, cared for in Veterans Health Administra

123 d ischemic stroke in a separate study of 509 ischemic stroke cases (202 cardioembolic [40%]) and 3028

124 METHODS AND Acute ischemic stroke cases entered into GWTG (Get With The Gu

125 Participants were 307677 individuals (8899 ischemic stroke cases) with measured weight and height a

126 6 842 cases), stroke from METASTROKE (12 389 ischemic stroke cases), type 2 diabetes mellitus from DI

127 46,735 intracerebral hemorrhage and 331,521 ischemic stroke cases.

128 Intra-arterial treatment (IAT) for acute ischemic stroke caused by intracranial arterial occlusio

129 ble clinical outcomes in patients with acute ischemic stroke caused by intracranial proximal occlusio

130 Acute ischemic stroke caused by proximal intracranial arterial

131 Among adults who had had a cryptogenic ischemic stroke, closure of a PFO was associated with a

132 the cerebral cortex of Malat1 KO mice after ischemic stroke compared with WT controls.

133 k factors among those hospitalized for acute ischemic stroke continued to increase from 2003-2004 thr

134 ct CV death, myocardial infarction (MI), and ischemic stroke (CV death/MI/ischemic cerebrovascular ac

135 ebral artery occlusion significantly reduced ischemic stroke damage and improved neurological outcome

136 Rates for 1-year ischemic stroke decreased after endarterectomy (absolute

137 care use after intracerebral hemorrhage and ischemic stroke differs between hospitals serving varyin

138 e or those who had previously experienced an ischemic stroke displayed a higher risk of stroke if war

139 mptomatic carotid web in patients with acute ischemic stroke due to intracranial large vessel occlusi

140 tion devices is beneficial for patients with ischemic stroke due to intracranial large-vessel occlusi

141 observed in 2.5% of the patients with acute ischemic stroke due to large vessel occlusion and were m

142 ssociated with reduced device thrombosis and ischemic stroke during ongoing LLH on Heart Mate II supp

143 y [female]) poorly discriminated the risk of ischemic stroke during sepsis (C statistic, 0.526).

144 validate transient ischemic attack and minor ischemic stroke electronic quality measures (eQMs) using

145 ts aged 18 to 45 years with first-ever acute ischemic stroke enrolled in the multicenter Italian Proj

146 atment for Small Core and Proximal Occlusion Ischemic Stroke (ESCAPE) trial used innovative imaging a

147 Ischemic stroke events were divided into early (</=55 ye

148 point was a composite of recurrent nonfatal ischemic stroke, fatal ischemic stroke, or early death a

149 0.84-0.89) but an increase in perioperative ischemic stroke from 0.52% in 2004 to 0.77% in 2013 (P f

150 Although ischemic stroke has been found to be associated with man

151 The treatment of acute ischemic stroke has undergone dramatic changes recently

152 Several trials involving patients with acute ischemic stroke have shown better functional outcomes wi

153 iated with a significant increase in risk of ischemic stroke (hazard ratio, 1.18; 95% confidence inte

154 Ischemic stroke, hemorrhagic stroke, any stroke, and str

155 emic heart disease, cerebrovascular disease, ischemic stroke, hemorrhagic stroke, hypertensive heart

156 s in this study are as follows: first, acute ischemic stroke hospitalization rates increased signific

157 vator) is effective in improving outcomes in ischemic stroke; however, there are few data on the use

158 y (HR, 0.83; 95% CI, 0.70-0.98; P=0.029) and ischemic stroke (HR, 0.76; 95% CI, 0.63-0.91; P=0.003).

159 scular events (HR, 1.37; 95% CI, 1.34-1.41), ischemic stroke (HR, 1.27; 95% CI, 1.23-1.32), hemorrhag

160 morrhage (HR, 2.4; 95% CI, 1.7-3.5) than for ischemic stroke (HR, 1.3; 95% CI, 1.2-1.5).

161 There was a weak association with ischemic stroke (HR: 1.36; 95% CI: 1.17 to 1.57), but no

162 Pioglitazone reduced risk for ischemic strokes (HR, 0.72; 95% CI, 0.57-0.91; P=0.005)

163 ociations between AF genetic risk scores and ischemic stroke in a separate study of 509 ischemic stro

164 es conferred long-term risk of mortality and ischemic stroke in both sexes and coronary heart disease

165 ne was effective for secondary prevention of ischemic stroke in nondiabetic patients with insulin res

166 The reduced risk of ischemic stroke in patients taking rivaroxaban, compared

167 amen ovale reduces the risk of recurrence of ischemic stroke in patients who have had a cryptogenic i

168 is a consistently documented risk factor for ischemic stroke in patients with atrial fibrillation (AF

169 n of ASIC1a reduces neuronal death following ischemic stroke in rodents.

170 Among patients with ischemic stroke in the anterior circulation undergoing t

171 al Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands (MR CLEAN) in whom th

172 al Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands.

173 al trial of endovascular treatment for acute ischemic stroke in the Netherlands.

174 3 years was positively associated with early ischemic stroke in women (HR, 1.10; 95% CI, 1.01-1.20) a

175 3 years was positively associated with early ischemic stroke in women (HR, 1.14; 95% CI, 1.06-1.23) a

176 f increasing hospitalization rates for acute ischemic stroke in young adults coexistent with increasi

177 al fibrillation who had experienced an acute ischemic stroke, inadequate therapeutic anticoagulation

178 surgery in the United States, perioperative ischemic stroke increased over time.

179 We found that ischemic stroke-induced DLS infarction produced signific

180 Consecutive patients with acute ischemic stroke initially admitted to a non-thrombectomy

181 evolution for thrombectomy in patients with ischemic stroke initially transferred to non-TCSCs.

182 PV1-mediated hypothermia by DHC on long-term ischemic stroke injury and functional outcome.

183 ecule inducers of GOT expression to mitigate ischemic stroke injury.

184 llular energetics and protect the brain from ischemic stroke injury.

185 come was stroke, and secondary outcomes were ischemic stroke, intracerebral hemorrhage, and subarachn

186 Ischemic stroke, intracranial hemorrhage, and death.

187 Ischemic stroke, intracranial hemorrhage, extracranial b

188 iological pathways, the genetic mechanism of ischemic stroke is still unclear.

189 rformed more than 6 hours after the onset of ischemic stroke is uncertain.

190 troke in patients who have had a cryptogenic ischemic stroke is unknown.

191 the risk of venous thromboembolism (VTE) and ischemic stroke (IS) due to statin and fibrate discontin

192 risk factors for myocardial infarction (MI), ischemic stroke (IS), and cardiac-related complications.

193 ortality, acute myocardial infarction (AMI), ischemic stroke (IS), hemorrhagic stroke, and new-onset

194 he complex relationship between migraine and ischemic stroke (IS).

195 d biomarkers with clinical utility for acute ischemic stroke (IS).

196 n associated with venous thromboembolism and ischemic stroke, its deficiency is associated with mild

197 stics increasing stroke risk include HDP for ischemic stroke, late menopause and gestational hyperten

198 hermore, GOT overexpression not only reduced ischemic stroke lesion volume but also attenuated neurod

199 the AVAIL study (Adherence Evaluation After Ischemic Stroke-Longitudinal) included 2083 ischemic str

200 cute brain injury and consequent impairment, ischemic stroke may also be associated with potentially

201 Ischemic strokes may accelerate long-term functional dec

202 therosclerotic occlusive disease is a common ischemic stroke mechanism.

203 We explored regional variation in 30-day ischemic stroke mortality and readmission rates and the

204 dition are ischemic heart disease, MR=105.5; ischemic stroke, MR=42.3; atrial fibrillation, MR=1.7; a

205 sonance imaging-classified neonatal arterial ischemic stroke (NAIS), arterial presumed perinatal isch

206 plicated in several neuronal disorders, like ischemic stroke, neuronal inflammation, and pathological

207 For ischemic stroke, novel therapeutic targets have continue

208 the intention-to-treat population, recurrent ischemic stroke occurred in 18 patients in the PFO closu

209 ng a median follow-up of 3.2 years, clinical ischemic stroke occurred in 6 of 441 patients (1.4%) in

210 Two patients developed an ischemic stroke, occurring 5 and 10 days after treatment

211 Recurrent ischemic stroke of undetermined cause occurred in 10 pat

212 h experience of using rt-PA in patients with ischemic stroke on a NOAC is limited, these preliminary

213 SIGNIFICANCE STATEMENT: During ischemic stroke or brain trauma, mitochondria can either

214 ere were adjusted annual decreases in 30-day ischemic stroke or death of 2.90% (95% CI, 2.63% to 3.18

215 nfarction, which was a composite of clinical ischemic stroke or silent brain infarction detected on i

216 igatran significantly decreased the risk for ischemic stroke or systemic embolism (p = 0.0004 and p =

217 The primary outcome was the recurrence of an ischemic stroke or TIA.

218 Patients with ischemic stroke or transient ischemic attack (TIA) are a

219 The risk of recurrence after an initial ischemic stroke or transient ischemic attack (TIA) may b

220 To determine whether, among patients with an ischemic stroke or transient ischemic attack and insulin

221 ) or placebo within 180 days of a qualifying ischemic stroke or transient ischemic attack and were fo

222 Eligible participants had a qualifying ischemic stroke or transient ischemic attack within 180

223 After an ischemic stroke or transient ischemic attack, patients a

224 ce without diabetes mellitus, after a recent ischemic stroke or transient ischemic attack.

225 ons (OR, 0.59; 95% CI: 0.48, 0.74; P < .01), ischemic stroke (OR, 0.25; 95% CI: 0.12, 0.50; P < .01),

226 Only WHRadjBMI increased risk of ischemic stroke (OR, 1.32; 95% CI, 1.03-1.70).

227 dial infarction, including stent thrombosis, ischemic stroke, or death from cardiovascular causes.

228 of recurrent nonfatal ischemic stroke, fatal ischemic stroke, or early death after randomization.

229 d incident ASCVD (ie, myocardial infarction, ischemic stroke, or fatal coronary heart disease).

230 ung adenocarcinoma transcript 1 (Malat1), in ischemic stroke outcome.

231 Liquid biopsies were collected from ischemic stroke patients (n = 39), neurologically asympt

232 rologic deficit and quality of life of acute ischemic stroke patients and that the therapeutic effect

233 e and brain functional connectivity in acute ischemic stroke patients and to explore the mechanism of

234 re measured in peripheral blood sampled from ischemic stroke patients at emergency department admissi

235 Ischemic Stroke-Longitudinal) included 2083 ischemic stroke patients enrolled from 82 US hospitals p

236 A total of 535 332 ischemic stroke patients from 1494 GWTG-Stroke hospitals

237 ed a prospective, in-depth analysis of adult ischemic stroke patients presenting to Queen Elizabeth C

238 Sixty-eight thrombi retrieved from ischemic stroke patients undergoing endovascular treatme

239 One third of acute ischemic stroke patients were functionally dependent or

240 In total, 44 acute ischemic stroke patients were randomly divided to the XX

241 A total of 16 901 ischemic stroke patients were treated with intravenous t

242 ODUCTION: We aimed to identify whether acute ischemic stroke patients with known complete reperfusion

243 Of 4782 acute ischemic stroke patients, 282 were underweight (BMI < 18

244 In ischemic stroke patients, being overweight or obese was

245 Previously accepted ischemic stroke preventative strategies, such as carotid

246 the warfarin arm maintained an unusually low ischemic stroke rate (0.73%).

247 age patient with AF, the threshold of annual ischemic stroke rate where the benefit of anticoagulatio

248 farin cohort experienced an unexpectedly low ischemic stroke rate, rendering the efficacy endpoints i

249 DS2-VASc score of 1, 76% of cohorts reported ischemic stroke rates <1% per year and only 18% of cohor

250 Oral anticoagulants decrease ischemic stroke rates in patients with atrial fibrillati

251 t retriever technique in patients with acute ischemic stroke remain uncertain because of lack of evid

252 oints were freedom from clinical evidence of ischemic stroke (reported here as the percentage of pati

253 Patients with acute ischemic stroke require immediate diagnostic workup and

254 Ischemic stroke results in excessive release of glutamat

255 y better reflect the life-long patterning of ischemic stroke risk in women.

256 In women, although ischemic stroke risk was similar in the 3 anticoagulant

257 women was partially offset by an increase in ischemic stroke risk.

258 second coprimary endpoint of post-procedure ischemic stroke/SE did achieve noninferiority (posterior

259 The ischemic stroke/SE rate was numerically higher with LAAC

260 at Malat1 plays critical protective roles in ischemic stroke.SIGNIFICANCE STATEMENT Accumulative stud

261 tely 20% of atrial fibrillation (AF)-related ischemic strokes, stroke is the first clinical manifesta

262 Rates of ischemic stroke/systemic embolism, death, and bleeding.

263 For the principal effectiveness end point of ischemic stroke/systemic embolism, no significant differ

264 h warfarin in terms of the risk of having an ischemic stroke/systemic embolism.

265 more likely to suffer from heart disease or ischemic stroke than adults without diabetes, yet standa

266 d showed significantly better outcomes after ischemic stroke than ck2beta(fl/fl) mice.

267 as associated with a lower rate of recurrent ischemic strokes than medical therapy alone during exten

268 of neutrophils and more specifically NETs in ischemic stroke thrombi.

269 n significantly reduced all-cause stroke and ischemic stroke through 77 days of follow-up

270 sis uses updated 2013 consensus criteria for ischemic stroke to examine the effect of pioglitazone on

271 ogic, and histologic features of HIV-related ischemic stroke to gain insight into the disease mechani

272 oramen ovale (PFO) and had had a cryptogenic ischemic stroke to undergo closure of the PFO (PFO closu

273 In patients with ischemic stroke transferred for thrombectomy, poor colla

274 comprising CV death, myocardial infarction, ischemic stroke, transient ischemic attack, and unstable

275 Of 42 887 patients with ischemic stroke treated with intravenous rt-PA within 4.

276 of EphA2 antagonist and a novel approach for ischemic stroke treatment.

277 In this period, 31 patients with similar ischemic strokes underwent endovascular treatment withou

278 any of the following events: cardiac death, ischemic stroke, ventricular tachycardia/ventricular fib

279 ome was combined end point of time to death, ischemic stroke, ventricular tachycardia/ventricular fib

280 The 6-month cumulative incidence of ischemic stroke was 3.0% (95% CI: 2.9% to 3.1%) in patie

281 dbrain to label specific neuronal types, and ischemic stroke was induced in the dorsolateral striatum

282 a cryptogenic stroke, the risk of subsequent ischemic stroke was lower among those assigned to PFO cl

283 al outcome at 2 years in patients with acute ischemic stroke was similar to that reported at 90 days

284 ted With Neurothrombectomy Devices for Acute Ischemic Stroke) was a prospective, multicenter, observa

285 t model of upper extremity impairments after ischemic stroke, we examined effects of motor rehabilita

286 In a mouse model of ischemic stroke, we found that hyperglycemia increased t

287 In men, the pooled relative risks of ischemic stroke were 1.19 (95% CI, 1.05-1.34) after andr

288 In women, the pooled relative risks of ischemic stroke were 1.80 (95% CI, 1.49-2.18) after any

289 Device thrombosis and ischemic stroke were associated with an increase in mean

290 capable hospitals, 7.5% of all patients with ischemic stroke were treated in the third quarter of 201

291 m coronary heart disease, fatal and nonfatal ischemic strokes) were recorded.

292 acute myocardial infarction (AMI), or acute ischemic stroke, were evaluated over time.

293 ficacy of intravenous rt-PA in patients with ischemic stroke who are taking NOACs.

294 c transformation (HT) in patients with acute ischemic stroke who receive intra-arterial thrombolysis.

295 use of thrombolytic therapy in patients with ischemic stroke who received anticoagulation with NOACs

296 iovascular death, myocardial infarction, and ischemic stroke with E/S compared with placebo/simvastat

297 Conclusion In the context of acute ischemic stroke with ipsilateral ICA nonattenuation at s

298 xamine the prevalence of patients with acute ischemic stroke with known history of AF who were not re

299 e coronary syndrome reduces the frequency of ischemic stroke, with a particularly large effect seen i

300 a magnetic resonance imaging-confirmed acute ischemic stroke within the anterior circulation and a hi